Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Re

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. IBM
6. MU
7. FDX
8. BLZE
9. NKE
10. PRIM

Go back to Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Re
(NASDAQ: ADAG) Delayed: 3.98 +0.14 (3.65%)
Previous Close $3.84    52 Week High $ 
Open $3.32    52 Week Low $ 
Day High $4.08    P/E N/A 
Day Low $3.32    EPS $ 
Volume 187,529       

(NASDAQ: ADAG) Delayed: 3.98 +0.14 (3.65%)
Previous Close $3.84    52 Week High $ 
Open $3.32    52 Week Low $ 
Day High $4.08    P/E N/A 
Day Low $3.32    EPS $ 
Volume 187,529